Cisplatin-loaded albumin nanoparticle and study their internalization effect by using β-cyclodextrin
The present study with aim at enhancing the therapeutic and anti-cancer properties of cisplatin (CPT)-loaded bovine serum albumin (BSA) nanoparticles. The BSA nanoparticles containing CPT (CPT-BSANPs) were successfully prepared by the desolvation technique. The physicochemical characterization of the CPT-BSANPs were used by Fourier transformed infrared spectroscopy (FTIR), scanning electron microscopy (SEM) and atomic force microscopy (AFM). The particle size of CPT-BSANPs was found less than 200 nm with 75.02 ± 0.15% entrapment efficiency (EE), while zeta potential and PDI were -17.6 mV and 0.2, respectively. In vitro release behavior of the CPT from the carrier suggests that about 64% of the drug gets released after 48 hrs. The anti-cancer activities of the CPT-BSANPs were tested on MCF-7 cell lines. Our studies show that CPT-BSANPs nanoparticles showed specific targeting and enhanced cytotoxicity to MCF-7 cells when compared to the bare CPT. Thus results suggest that CPT-BSANPs fallowed caveolae-mediated endocytosis, it may become better option for intracellular delivery of anticancer drug.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Journal of receptor and signal transduction research - 41(2021), 4 vom: 03. Aug., Seite 393-400 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tiwari, Rahul [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 20.12.2021 Date Revised 20.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/10799893.2020.1817077 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314729054 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314729054 | ||
| 003 | DE-627 | ||
| 005 | 20231225153351.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/10799893.2020.1817077 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1049.xml |
| 035 | |a (DE-627)NLM314729054 | ||
| 035 | |a (NLM)32900251 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tiwari, Rahul |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cisplatin-loaded albumin nanoparticle and study their internalization effect by using β-cyclodextrin |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.12.2021 | ||
| 500 | |a Date Revised 20.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The present study with aim at enhancing the therapeutic and anti-cancer properties of cisplatin (CPT)-loaded bovine serum albumin (BSA) nanoparticles. The BSA nanoparticles containing CPT (CPT-BSANPs) were successfully prepared by the desolvation technique. The physicochemical characterization of the CPT-BSANPs were used by Fourier transformed infrared spectroscopy (FTIR), scanning electron microscopy (SEM) and atomic force microscopy (AFM). The particle size of CPT-BSANPs was found less than 200 nm with 75.02 ± 0.15% entrapment efficiency (EE), while zeta potential and PDI were -17.6 mV and 0.2, respectively. In vitro release behavior of the CPT from the carrier suggests that about 64% of the drug gets released after 48 hrs. The anti-cancer activities of the CPT-BSANPs were tested on MCF-7 cell lines. Our studies show that CPT-BSANPs nanoparticles showed specific targeting and enhanced cytotoxicity to MCF-7 cells when compared to the bare CPT. Thus results suggest that CPT-BSANPs fallowed caveolae-mediated endocytosis, it may become better option for intracellular delivery of anticancer drug | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Albumin | |
| 650 | 4 | |a MCF-7 cells | |
| 650 | 4 | |a cisplatin | |
| 650 | 4 | |a nanoparticles: drug delivery | |
| 650 | 7 | |a Albumins |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Tetrazolium Salts |2 NLM | |
| 650 | 7 | |a Thiazoles |2 NLM | |
| 650 | 7 | |a beta-Cyclodextrins |2 NLM | |
| 650 | 7 | |a Serum Albumin, Bovine |2 NLM | |
| 650 | 7 | |a 27432CM55Q |2 NLM | |
| 650 | 7 | |a thiazolyl blue |2 NLM | |
| 650 | 7 | |a EUY85H477I |2 NLM | |
| 650 | 7 | |a betadex |2 NLM | |
| 650 | 7 | |a JV039JZZ3A |2 NLM | |
| 650 | 7 | |a Cisplatin |2 NLM | |
| 650 | 7 | |a Q20Q21Q62J |2 NLM | |
| 700 | 1 | |a Viswanathan, Kaliyaperumal |e verfasserin |4 aut | |
| 700 | 1 | |a Gour, Vishal |e verfasserin |4 aut | |
| 700 | 1 | |a Vyas, Suresh Prasad |e verfasserin |4 aut | |
| 700 | 1 | |a Soni, Vandana |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of receptor and signal transduction research |d 1998 |g 41(2021), 4 vom: 03. Aug., Seite 393-400 |w (DE-627)NLM075607417 |x 1532-4281 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2021 |g number:4 |g day:03 |g month:08 |g pages:393-400 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/10799893.2020.1817077 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2021 |e 4 |b 03 |c 08 |h 393-400 | ||